Evidence map›Paper›PMID 28490211›Full record

ReviewHuman gene therapy2017

Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes?

Nolan Brown, Liujiang Song, Nageswara R Kollu, Matthew L Hirsch

Abstract readReview
In one paragraph

Review in Human gene therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. AAV vector development, back to the future.Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Designing molecules: directing stem cell differentiation.Frontiers in bioengineering and biotechnology · 2024
    Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. AAV vectors: The Rubik's cube of human gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2022
    Review
  15. Article
  16. Article
  17. Tissue and cell-type-specific transduction using rAAV vectors in lung diseases.Journal of molecular medicine (Berlin, Germany) · 2021
    Review
  18. Review
  19. Progress of cationic gene delivery reagents for non-viral vector.Applied microbiology and biotechnology · 2021
    Review
  20. High-ThroughputHuman gene therapy · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Nolan Brown1 Gene Therapy Center, University of North Carolina at Chapel Hill , North Carolina.
Liujiang Song1 Gene Therapy Center, University of North Carolina at Chapel Hill , North Carolina.
Nageswara R Kollu1 Gene Therapy Center, University of North Carolina at Chapel Hill , North Carolina.
Matthew L Hirsch1 Gene Therapy Center, University of North Carolina at Chapel Hill , North Carolina.

Funding

Rational and Combinatorial Engineering of AAV VectorsR01AI072176 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIRSCH, MATTHEW LOUIS, SAMULSKI, RICHARD J · 2008 to 2017
$3.7M
Overcoming our clinical complications: AAV vector design for the treatment of DMDR01AR064369 · NIAMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HIRSCH, MATTHEW LOUIS, SAMULSKI, RICHARD J · 2013 to 2017
$1.6M
NIAID NIH HHS R01 AI072176NIAMS NIH HHS R01 AR064369
6 · The paper itself

Abstract

The infusion of healthy stem cells into a patient-termed "stem-cell therapy"-has shown great promise for the treatment of genetic and non-genetic diseases, including mucopolysaccharidosis type 1, Parkinson's disease, multiple sclerosis, numerous immunodeficiency disorders, and aplastic anemia. Stem cells for cell therapy can be collected from the patient (autologous) or collected from another "healthy" individual (allogeneic). The use of allogenic stem cells is accompanied with the potentially fatal risk that the transplanted donor T cells will reject the patient's cells-a process termed "graft-versus-host disease." Therefore, the use of autologous stem cells is preferred, at least from the immunological perspective. However, an obvious drawback is that inherently as "self," they contain the disease mutation. As such, autologous cells for use in cell therapies often require genetic "correction" (i.e., gene addition or editing) prior to cell infusion and therefore the requirement for some form of nucleic acid delivery, which sets the stage for the AAV controversy discussed herein. Despite being the most clinically applied gene delivery context to date, unlike other more concerning integrating and non-integrating vectors such as retroviruses and adenovirus, those based on adeno-associated virus (AAV) have not been employed in the clinic. Furthermore, published data regarding AAV vector transduction of stem cells are inconsistent in regards to vector transduction efficiency, while the pendulum swings far in the other direction with demonstrations of AAV vector-induced toxicity in undifferentiated cells. The variation present in the literature examining the transduction efficiency of AAV vectors in stem cells may be due to numerous factors, including inconsistencies in stem-cell collection, cell culture, vector preparation, and/or transduction conditions. This review summarizes the controversy surrounding AAV vector transduction of stem cells, hopefully setting the stage for future elucidation and eventual therapeutic applications.

Indexed as

Anemia, AplasticCell- and Tissue-Based TherapyDependovirusGenetic TherapyGenetic VectorsHumansImmunologic Deficiency SyndromesMucopolysaccharidosis IMultiple SclerosisParkinson DiseaseStem CellsStem Cell TransplantationTransduction, GeneticTransplantation, AutologousAAV vectorsgene therapyITRstem cellstem cell therapy

Identifiers

PMID28490211
PMCPMC5488260

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.